Key Takeaways
The U.S. Food and Drug Administration (FDA) has approved a label expansion for argenx SE’s Vyvgart and Vyvgart Hytrulo, making it the first treatment for all adult patients with generalized myasthenia gravis (gMG), a rare and chronic autoimmune disease that causes debilitating muscle weakness.
"Today’s approval means that all adult gMG patients, regardless of serotype, can now benefit from VYVGART’s rapid onset, sustained disease control, and favorable safety profile,” said Luc Truyen, Chief Medical Officer at argenx. "For clinicians, this simplifies treatment decisions, representing a major advancement in reaching as many patients living with gMG as possible.”
The approval was based on the Phase 3 ADAPT SERON study, the largest trial to date for gMG patients who lack the common anti-acetylcholine receptor (AChR) antibodies. The study demonstrated a statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores, with patients showing a mean improvement of 3.35 points from baseline at week four (p=0.0068). The treatment was well-tolerated, with a safety profile consistent with previous studies.
This decision significantly expands Vyvgart's addressable market, which previously only covered the roughly 80 percent of gMG patients who are AChR-antibody positive. The new label adds patients who are positive for anti-MuSK or anti-LRP4 antibodies, as well as those who are triple seronegative, a group that has historically been excluded from many clinical trials and faced a higher disease burden.
Generalized myasthenia gravis can impair fundamental aspects of life, including speech, vision, swallowing, and breathing. For the approximately 20 percent of patients without AChR antibodies, diagnosis and management have been particularly challenging.
“For too long, gMG patients who do not have detectable AChR-Ab have been left behind, feeling disengaged and excluded from receiving treatments that specifically treat their disease, which has led to patients experiencing a higher burden of suffering,” said Allison Foss, Executive Director of the Myasthenia Gravis Association. “This approval validates that gMG patients without AChR-Ab can benefit from a targeted treatment, bringing a sense of hope to thousands in our community.”
Vyvgart, a neonatal Fc receptor (FcRn) blocker, works by reducing the number of circulating IgG autoantibodies that cause the disease. It is available as both an intravenous infusion (Vyvgart) and a subcutaneous injection (Vyvgart Hytrulo).
The expanded approval solidifies argenx's leadership in the gMG space and is expected to be a significant growth driver for the company. Investors will be watching the initial sales uptake in this expanded patient population, with the company's patient support program, My VYVGART Path, in place to facilitate access.
This article is for informational purposes only and does not constitute investment advice.
